Redeye provides its comment on Mendus’ Q4 2023 report. We judge that the most critical catalysts for the share will be interim readouts and top-line data from the company’s planned phase II trial in AML maintenance, combining vididencel and oral azacytidine. We do some housekeeping in our model, though our estimates and valuation remain largely unchanged.